AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8192275
Drug: 2 grams
RxNorm normalized name: phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 grams of oral vitamin C for one month
Trial: 29689025
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab (IVR) monotherapy
Trial: 22049798
Drug: Paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg/d for 30 days
Trial: 16527402
Drug: Replacement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Replacement of baseline health-state-related measures with post-treatment measures
Trial: 8612391
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg moclobemide
Trial: 8612391
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of entacapone and moclobemide
Trial: 6443775
Drug: Reference antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference antibiotics (gentamicin, tobramycin, amikacin, or ticarcillin)
Trial: 6443775
Drug: Reference antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference antibiotics
Trial: 6443775
Drug: Cefsulodin or
RxNorm normalized name: cefsulodin
DrugBank: Cefsulodin (DB13499)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefsulodin or reference antibiotics
Trial: 21415134
Drug: Combination antithrombotic
RxNorm normalized name: ANTITHROMBIN III,RECOMBINANT
DrugBank: Antithrombin Alfa (DB11166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination antithrombotic therapy (subcutaneous idraparinux 2.5 mg weekly + antiplatelet therapy)
Trial: 21415134
Drug: Anticoagulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation therapy only (dose-adjusted vitamin K antagonists)
Trial: 21415134
Drug: Combination antithrombotic
RxNorm normalized name: ANTITHROMBIN III,RECOMBINANT
DrugBank: Antithrombin Alfa (DB11166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination antithrombotic therapy
Trial: 18502255
Drug: UV irradiation
RxNorm normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UV irradiation (suberythemal doses, twice weekly for 12 weeks)
Trial: 16553686
Drug: Customized exercise
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Customized exercise programme (12-month programme of cardiorespiratory, stretching, muscle-strengthening and relaxation exercises, 2 sessions per week, total of 3 hours weekly)
Trial: 8446047
Drug: Hypocaloric glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric glucose infusion
Trial: 3097383
Drug: Intravenous 100
RxNorm normalized name: immune globulin intravenous 100 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 100 micrograms of human corticotropin-releasing factor
Trial: 29423501
Drug: Sulindac (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac (150 mg twice daily) and Erlotinib (75 mg daily)
Trial: 24057928
Drug: SEQ-FLUOX (fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEQ-FLUOX (fluoxetine 20mg, starting 8 weeks before quit date and continuing for 8 weeks after quit date + TNP)
Trial: 24057928
Drug: ST-FLUOX (fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ST-FLUOX (fluoxetine 20mg, starting 2 weeks before quit date and continuing for 8 weeks after quit date + TNP)
Trial: 20013016
Drug: Micafungin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin therapy
Trial: 18595990
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 400 mug of cobalamin
Trial: 11413538
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (vincristine, actinomycin-D, cyclophosphamide - VAC)
Trial: 11413538
Drug: IRS-III/IV treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRS-III/IV treatments
Trial: 11413538
Drug: IRS-I/II treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRS-I/II treatments
Trial: 11413538
Drug: Local therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local therapy (surgery and RT)
Trial: 9001297
Drug: Inhaled salmeterol
RxNorm normalized name: salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol 50 microg every 12 h
Trial: 9001297
Drug: Oral theophylline
RxNorm normalized name: theophylline Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral theophylline (individually dose‐titrated sustained-release)
Trial: 8394627
Drug: Erythromycin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (0.5 g b.i.d.)
Trial: 27118206
Drug: Increase of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase of daily GH dose (IGF-1 target level of 1 to 2 SDS)
Trial: 27118206
Drug: Decrease of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decrease of daily GH dose (IGF-1 target level of -2 to -1 SDS)
Trial: 19298639
Drug: Subcutaneous (s.c.)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (s.c.) administration of darbepoetin alfa
Trial: 19298639
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) administration of darbepoetin alfa
Trial: 19298639
Drug: Both s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both s.c. and i.v. administration of darbepoetin alfa
Trial: 8392826
Drug: Granisetron tablet
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron tablet (2 mg)
Trial: 3107546
Drug: Prazosin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin therapy (1 to 8 mg/day for 8 weeks)
Trial: 3107546
Drug: Propranolol therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol therapy (20 to 240 mg/day for 8 weeks)
Trial: 29220885
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with disease‐modifying drugs and MEB
Trial: 29220885
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy using MEB medication and iron
Trial: 26969836
Drug: Lettuce juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lettuce juice beverage containing approximately 200 mg nitrate per day (test)
Trial: 20627979
Drug: 225 IU
RxNorm normalized name: Ascorbic Acid/Calcium Pantothenate/Cyanocobalamin/Iron/Niacin/Pyridoxine/Riboflavin/Thiamine/Vitamin A/Vitamin D/Vitamin E/Zinc 200 MG-18.4 MG-0.005 MG-12 MG-100 MG-4.1 MG-10 MG-0.3 MG-10000 IU-400 IU-225 IU-1.5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225 IU starting dose of recombinant FSH (r‐FSH)
Trial: 20627979
Drug: 150 IU
RxNorm normalized name: Follitropin Beta 150 IU/0.5 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 IU starting dose of recombinant FSH (r‐FSH)
Trial: 19120955
Drug: Current American
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current American Board of Internal Medicine Mini-CEX form
Trial: 21775910
Drug: 530 mg
RxNorm normalized name: citric acid 1530 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 530 mg of concentrated valerian extract twice a day for 4 weeks
Trial: 9855317
Drug: Fasting conditions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting conditions (PZA 30 mg/kg)
Trial: 9855317
Drug: Antacids (PZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacids (PZA 30 mg/kg)
Trial: 9855317
Drug: High-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat meal (PZA 30 mg/kg)
Trial: 3289717
Drug: Alprazolam (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (2.4 mg average daily dose)
Trial: 3289717
Drug: Amitriptyline hydrochloride
RxNorm normalized name: Amitriptyline Hydrochloride
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amitriptyline hydrochloride (135 mg average daily dose)
Trial: 27632863
Drug: Static stretching
RxNorm normalized name: Mederma Stretch Mark Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Static stretching (SS) program performed 3 times weekly for 4 weeks
Trial: 1381210
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg per day of medroxyprogesterone acetate (MPA)
Trial: 1381210
Drug: Chemotherapy regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimen (cisplatin, 5‐fluorouracil, methotrexate, bleomycin, vincristine)
Trial: 25157723
Drug: Self-monitoring of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-monitoring of blood pressure combined with an individualized self-titration algorithm.
Trial: 25157723
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (routine blood pressure measurement and adjustment of medication if necessary).
Trial: 25157723
Drug: Self-monitoring with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-monitoring with self-titration of antihypertensive medication.
Trial: 23737510
Drug: mirtazapine 30
RxNorm normalized name: mirtazapine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mirtazapine 30 mg/day
Trial: 23737510
Drug: mirtazapine 15
RxNorm normalized name: mirtazapine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mirtazapine 15 mg/day
Trial: 17492340
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (7 sessions of IPL, 9 sessions of low intense diode light, and biostimulation by drugs)
Trial: 17492340
Drug: Monotherapy (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (7 sessions of IPL only)
Trial: 17213792
Drug: Tadalafil 20
RxNorm normalized name: tadalafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 20 mg per os on demand for 3 months (Group A)
Trial: 17213792
Drug: Tadalafil 20
RxNorm normalized name: tadalafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 20 mg per os on weekly fixed days (Monday‐Wednesday‐Friday) for 3 months (Group B)
Trial: 11422338
Drug: Pregabalin (PGB)
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin (PGB) 50-600 mg/day
Trial: 8508556
Drug: Prednisone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (30 mg, alternate days)
Trial: 8508556
Drug: Piroxicam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (20 mg, daily)
Trial: 2950827
Drug: PDC-HDC diacetate
RxNorm normalized name: Diflorasone Diacetate
DrugBank: Diflorasone (DB00223)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PDC-HDC diacetate (306.5 mg over five weeks, followed by 960 mg during maintenance)
Trial: 27076209
Drug: Memantine (MEM)
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Memantine (MEM) 20 mg p.o.
Trial: 24722932
Drug: Telemonitoring (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemonitoring (daily measuring of health parameters including ECG, blood pressure, weight, and self-assessment)
Trial: 14710772
Drug: 1.0% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0% chlorhexidine gel (Period C)
Trial: 10910607
Drug: MMR and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR and JE vaccines nonsimultaneously (Group A)
Trial: 10910607
Drug: MMR and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR and JE vaccines simultaneously (Group B)
Trial: 1699597
Drug: Cornflakes (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cornflakes (350 g/d, providing 10.33 g RS/d)
Trial: 1699597
Drug: Rice Krispies
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice Krispies (380 g/d, providing 0.86 g RS/d)
Trial: 7365045
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (exposure + response prevention) for 2 weeks after initial treatments
Trial: 27759458
Drug: Amberen dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amberen dietary supplement
Trial: 15964160
Drug: CEE/MPA 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE/MPA 5 mg
Trial: 15964160
Drug: CEE/MPA 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE/MPA 2.5 mg
Trial: 10687548
Drug: Static surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Static surface (gel pad)
Trial: 8681149
Drug: 5-cc saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-cc saline bolus
Trial: 2028354
Drug: Analgesic/anti-inflammatory combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic/anti-inflammatory combined medication (Myprodol; Rio Ethicals)
Trial: 2028354
Drug: Anti-inflammatory medication
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory medication (Voltaren; Geigy)
Trial: 16154735
Drug: Regular intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular intermittent epidural boluses (5 mL every half hour)
Trial: 16154735
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion of levobupivacaine 0.1% with fentanyl 2 microg/mL at a rate of 10 mL/h
Trial: 10421644
Drug: Somatostatin (SMT)
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (SMT) infusion (250 micrograms/h) for 5 days
Trial: 10421644
Drug: Somatostatin (SMT)
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (SMT) infusion (250 micrograms/h) for 5 days + sclerotherapy
Trial: 27059729
Drug: Tofacitinib 10
RxNorm normalized name: tofacitinib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 10 mg twice daily for 12 weeks
Trial: 25538468
Drug: Chlorhexidine gel
RxNorm normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gel after scaling and root planing (SRP)
Trial: 8450326
Drug: Nicardipine (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (0.15 mg/kg/hr by continuous infusion for up to 14 days)
Trial: 3828486
Drug: pH 2.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH 2.3 solution of 0.5 mg triazolam
Trial: 3828486
Drug: pH 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH 6.0 solution of 0.5 mg triazolam
Trial: 3828486
Drug: pH 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH 6.0 solution of 0.5 mg triazolam during cimetidine treatment (1200 mg day-1)
Trial: 30957525
Drug: Cognitive‐Behavioral Therapy‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐Behavioral Therapy‐based integrated treatment/management program (active treatment condition)
Trial: 27126198
Drug: 54 mg
RxNorm normalized name: aspirin 454 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 54 mg genistein daily for 1 year
Trial: 25519790
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of antiretroviral therapy (ART) within 2 weeks
Trial: 25519790
Drug: Deferred initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Deferred initiation of antiretroviral therapy (ART) starting a median of 1.3 years after enrollment
Trial: 12632024
Drug: Low-dose aprotinin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose aprotinin (280 mg)
Trial: 10692268
Drug: Amlodipine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (mean dose, 9 mg/d)
Trial: 10692268
Drug: Enalapril (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (mean dose, 17 mg/d)
Trial: 8225688
Drug: Nocloprost (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nocloprost (200 micrograms) given twice daily for 8 days
Trial: 31248676
Drug: Epinephrine dosing
RxNorm normalized name: epinephrine Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine dosing interval less than 3 minutes
Trial: 31248676
Drug: Epinephrine dosing
RxNorm normalized name: epinephrine Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine dosing interval 3 to less than 4 minutes
Trial: 31248676
Drug: Epinephrine dosing
RxNorm normalized name: epinephrine Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine dosing interval 4 to less than 5 minutes
Trial: 31248676
Drug: Epinephrine dosing
RxNorm normalized name: epinephrine Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine dosing interval greater than or equal to 5 minutes
Trial: 25425373
Drug: Sequential arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential arm - 3 transabdominal cervical length measurements obtained, transvaginal sonography performed if images were inadequate or if any measurement was 3 cm or less
Trial: 8151462
Drug: Ceftriaxone, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone, 50 mg/kg intramuscularly
Trial: 8151462
Drug: Amoxicillin, 20
RxNorm normalized name: Amoxicillin, 200 mg oral tablet, chewable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin, 20 mg/kg/dose orally for six doses
Trial: 21935965
Drug: Modified-release zaleplon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release zaleplon 15 mg (SKP-1041A, SKP-1041B, SKP-1041C)
Trial: 21935965
Drug: Modified-release zaleplon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release zaleplon 15 mg (SKP-1041A, SKP-1041B)
Trial: 21935965
Drug: Immediate-release zaleplon
RxNorm normalized name: Zaleplon
DrugBank: Zaleplon (DB00962)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate-release zaleplon 10 mg
Trial: 21935965
Drug: Modified-release zaleplon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release zaleplon 15 mg (SKP-1041)
Trial: 11529537
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment (GH) at a dose of 0.15 IU kg(-1) per day for 3 years (Group A: discontinuous, Group B: control for 1 year then continuous, Group C: continuous)
Trial: 11529537
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment (GH) (Group A: discontinuous, Group B: continuous after 1 year, Group C: continuous)
Trial: 11529537
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment (GH) (Group A: discontinuous, Group B: continuous, Group C: continuous)
Trial: 11529537
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment (GH) (Group A: discontinuous)
Trial: 9555791
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid-based lipid emulsion (Omegavenous; 200 ml/day with 4.2 gm of both EPA and DHA)
Trial: 9555791
Drug: Conventional omega-6-lipid
RxNorm normalized name: Omega 6 acids
DrugBank: Omega-6 fatty acids (DB13168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional omega-6-lipid emulsion (Lipovenous; EPA+DHA < 0.1 gm/100 ml)
Trial: 2337211
Drug: Control (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (2 ml saline with 0.5% bupivacaine)
Trial: 204183
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: diet treatment from a clinic nutritionist with cooperation of the subject's private physician
Trial: 204183
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: referral for treatment by a private physician
Trial: 23596811
Drug: Nimodipine (drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (drug group)
Trial: 21550374
Drug: 23-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent pneumococcal polysaccharide vaccine (PPV), Haemophilus influenzae type b conjugate vaccine, and tetanus toxoid
Trial: 21550374
Drug: PPV at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPV at 7 or 17 weeks and second dose at 3 years of age
Trial: 11768322
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day alpha-tocopherol for 14 days